

Applicants : Graham P. Allaway, et al.
Serial No. : Not Yet Known
Filed : May 9, 2001
Page 3

inhibit HIV-1 infection of a CD4+ cell.--

--55. (New) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with the agent of claim 49 or 50 in an amount and under conditions such that fusion of HIV-1 or an HIV-1 infected cell to the CD4+ cell is inhibited, so as to thereby inhibit HIV-1 infection of the CD4+ cell.--

Remarks:


Claims 1-48 are pending in the subject application. Applicants have hereinabove canceled claims 1-48 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application and added claims 49-55. Support for this amendment may be found inter alia in the specification as follows: claims 49-52: page 13, lines 2-35; page 16, lines 18-21; claim 53: page 13, lines 2-3; claim 54: page 14, lines 16-19; and claims 55: page 16, lines 4-20. These amendments do not involve any issue of new matter. Accordingly, entry of this amendment is respectfully requested such that claims 49-55 will be pending.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

Applicants : Graham P. Allaway, et al.
Serial No. : Not Yet Known
Filed : May 9, 2001
Page 4

No fee, in addition to the enclosed \$490.00 fee which includes the filing fee of \$355.00 and the \$135.00 fee for additional claims, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Applicant Graham P. Allaway et al. 51320-AB JPW/SHS
Progenics - 2048 File No. Atty.
Client May 9, 2001
Date

Kindly acknowledge receipt of the accompanying

Continuation Application Under 37 C.F.R. §1.53(b) in connection with Graham P. Allaway et al., U.S. Serial No. Not Yet Known, filed May 9, 2001 for USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION, including Specification (pgs. 1-81), Claims (pgs. 82-88), Abstract (pg. 89), Formal Drawings (12 sheets), 1 loose set of formal drawings, a copy of the Declaration and Power of Attorney, Transmittal Letter in Triplicate, a Preliminary Amendment, a check in the amount of \$490.00, and Express Mail Certificate of Mailing bearing Label No. EJ 947 034 465 US, dated May 9, 2001.

by placing your receiving date stamp hereon and returning to us.

Applicant Graham P. Allaway et al. 51320-AB JPW/SHS
Progenics - 2048 File No. Atty.
Client May 9, 2001
Date

Kindly acknowledge receipt of the accompanying

Continuation Application Under 37 C.F.R. §1.53(b) in connection with Graham P. Allaway et al., U.S. Serial No. Not Yet Known, filed May 9, 2001 for USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION, including Specification (pgs. 1-81), Claims (pgs. 82-88), Abstract (pg. 89), Formal Drawings (12 sheets), 1 loose set of formal drawings, a copy of the Declaration and Power of Attorney, Transmittal Letter in Triplicate, a Preliminary Amendment, a check in the amount of \$490.00, and Express Mail Certificate of Mailing bearing Label No. EJ 947 034 465 US, dated May 9, 2001.

JC997 U.S. PTO
09/852238

by placing your receiving date stamp hereon and returning to us

